Sol-Gel Technologies (SLGL) Payables (2016 - 2025)
Sol-Gel Technologies (SLGL) reported Payables of $735000.0 for Q4 2025, down 79.53% year-over-year from $3.6 million in Q4 2024, and down 11.23% on a QoQ basis from $828000.0 in Q3 2025.
Sol-Gel Technologies (SLGL) has 10 years of Payables data on file, last reported at $735000.0 in Q4 2025.
- Quarterly Payables fell 79.53% year-over-year to $735000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $735000.0 (down 79.53% YoY) and the FY2025 annual result came in at $735000.0, down 79.53% from the prior year.
- Payables eased to $735000.0 in Q4 2025 per SLGL's latest filing, from $828000.0 in the prior quarter.
- Across five years, Payables topped out at $3.6 million in Q4 2024 and bottomed at $154000.0 in Q4 2023.
- The 5-year median for Payables is $750500.0 (2021), against an average of $906700.0.
- The widest annual swing landed in 2022, when Payables slumped 87.06%; it then surged 2231.17% in 2024.
- Tracing SLGL's Payables over 5 years: stood at $766000.0 in 2021, then tumbled by 67.23% to $251000.0 in 2022, then plunged by 38.65% to $154000.0 in 2023, then surged by 2231.17% to $3.6 million in 2024, then slumped by 79.53% to $735000.0 in 2025.
- Per Business Quant, the three latest SLGL Payables figures stand at $735000.0 (Q4 2025), $828000.0 (Q3 2025), and $1.2 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | 735,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 735,000.00 |
| Sep 30, 2025 | 828,000.00 |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 438,000.00 |
| Dec 31, 2024 | 3.59 Mn |
| Sep 30, 2024 | 1.52 Mn |
| Jun 30, 2024 | 679,000.00 |
| Mar 31, 2024 | 582,000.00 |
| Dec 31, 2023 | 154,000.00 |
| Sep 30, 2023 | 234,000.00 |
| Jun 30, 2023 | 461,000.00 |
| Mar 31, 2023 | 339,000.00 |
| Dec 31, 2022 | 251,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Jun 30, 2022 | 860,000.00 |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 766,000.00 |
| Sep 30, 2021 | 1.29 Mn |
| Jun 30, 2021 | 1.35 Mn |
| Mar 31, 2021 | 1.62 Mn |
| Dec 31, 2020 | 1.20 Mn |
| Sep 30, 2020 | 1.12 Mn |
| Jun 30, 2020 | 1.23 Mn |
| Mar 31, 2020 | 1.93 Mn |
| Dec 31, 2019 | 1.71 Mn |
| Sep 30, 2019 | 2.46 Mn |
| Jun 30, 2019 | 1.94 Mn |
| Mar 31, 2019 | 4.09 Mn |
| Dec 31, 2018 | 2.92 Mn |
| Sep 30, 2018 | 3.36 Mn |
| Jun 30, 2018 | 2.11 Mn |
| Mar 31, 2018 | 444,000.00 |
| Dec 31, 2017 | 65.87 Mn |
| Dec 31, 2016 | 38.01 Mn |